| Literature DB >> 31942536 |
David J Kedziora1,2, Romesh Abeysuriya3, Cliff C Kerr1, George L Chadderdon4, Vlad-Ștefan Harbuz5, Sarah Metzger6, David P Wilson6, Robyn M Stuart7.
Abstract
Introduction: Cascades, which track the progressive stages of engagement on the path towards a successful outcome, are increasingly being employed to quantitatively assess progress towards targets associated with health and development responses. Maximizing the proportion of people with successful outcomes within a budget-constrained context requires identifying and implementing interventions that are not only effective, but also cost-effective.Entities:
Keywords: cascades; modeling; optimization; service delivery
Year: 2019 PMID: 31942536 PMCID: PMC6944813 DOI: 10.12688/gatesopenres.13031.2
Source DB: PubMed Journal: Gates Open Res ISSN: 2572-4754
Figure 1. A typical cascade presents the proportion of the total target population that have attained each of the sequential steps of engagement in the path towards a successful outcome.
Figure 2. The types of questions designed to be answered by the Cascade Analysis Tool.
Figure 3. The software architecture of the Cascade Analysis Tool.
Figure 4. A generic treatment cascade (panel A), which is translated (panel B) into a compartmental model (panel C).
Figure 5. (Panel A) Input data on the state of the hypertension cascade; (Panel b) Illustrative hypertension cascade model with flow rates described in blue text; (Panel C) Cascade representation of the hypertension model with the 2016 values as per the input data and the 2017 values derived from applying the flow rates in Panel B.
Figure 6. Illustration of the data entry book for the hypertension example depicted in Figure 5.
Illustrative data on interventions for the hypertension example presented in Figure 4.
| Intervention | Target cascade
| Number
| Unit
| Baseline
| Impact |
|---|---|---|---|---|---|
| Pharmacy testing | Undiagnosed | 1,430 tested | $5 | $7,150 | • 50 diagnosed (3.5% yield)
|
| Clinic testing | Undiagnosed | 1,000 tested | $20 | $20,000 | • 35 diagnosed (3.5% yield)
|
| Outreach testing | Undiagnosed | 150 tested | $15 | $2,250 | • 22 diagnosed (15% yield)
|
| Treatment & lifestyle
| Diagnosed, not
| 110 counseled | $25 | $2,750 | • All those counseled start
|
| Adherence &
| Treated, not
| 200 counseled | $25 | $5,000 | • 30% of those counseled attain
|
| Retention
| All treated | 600 covered | $25 | $15,000 | • 96% treatment retention vs
|
*Baseline investment is calculated here by multiplying the number of people covered by the unit cost.
Illustrative scenarios showing different intervention scale-up options, based on the treatment cascade introduced in Figure 3.
| Intervention to
| Scaled-up
| Number
| Impact | Cascade in 2017
|
|---|---|---|---|---|
| Pharmacy testing | $17,150 | 3,430 tested | • 120 diagnosed
| • Diagnosed: 1853 (4%)
|
| Clinic testing | $30,000 | 1,500 tested | • 53 diagnosed
| • Diagnosed: 1800 (1%)
|
| Outreach testing | $12,250 | 817 tested | • 122 diagnosed
| • Diagnosed: 1883 (6%)
|
| Treatment & lifestyle
| $12,750 | 510 counseled | • 510 start treatment | • Diagnosed: 1783 (-)
|
| Adherence & lifestyle
| $15,000 | 600 counseled | • 180 attain control | • Diagnosed: 1783 (-)
|
| Retention
| $25,000 | 1000 covered | • 62 lost to follow-up | • Diagnosed: 1853 (-)
|
Figure 7. The state of the illustrative hypertension cascade in 2017 under the 6 different scale-up options presented in Table 2.
Figure 8. Optimal allocations for achieving difference targets related to the illustrative hypertension example.